Paul L Berns
CIK 1202769 · See Remarks · last filed 2026-08-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$245.07M
Companies
13
Total Filings
101
Lifetime Open-Market Net
$121.97M
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
Filer Profile
Reported Address
C/O NEUMORA THERAPEUTICS, INC.260 ARSENAL PLACE, SUITE 1
WATERTOWN, MA 02472
Related Filers
ARCH Venture Fund XIII, L.P. — 2 joint filings, latest 2026-03-09
ARCH Venture Partners XIII, LLC — 2 joint filings, latest 2026-03-09
Kristina Burow — 2 joint filings, latest 2026-03-09
Keith Crandell — 2 joint filings, latest 2026-03-09
Steven Gillis — 2 joint filings, latest 2026-03-09
Robert Nelsen — 2 joint filings, latest 2026-03-09
Clinton Bybee — 1 joint filings, latest 2026-03-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NMRA | See Remarks | 7,528,282 | $0.50 | $3.76M | -$57.9K | 8 | 2026-08-21 |
| KARD | Director | 15,062,741 | $15.35 | $231.21M | $20.00M | 2 | 2026-06-24 |
| LYEL | 10%+ Owner | 910,317 | $8.92 | $8.12M | $112.50M | 1 | 2026-03-09 |
| Metsera, Inc. (MTSR) Delisted | Director | 0 | $70.50 | $0 | $14.22M | 3 | 2025-11-13 |
| Unity Biotechnology, Inc. (UBX) Delisted | Director | 326 | $0.20 | $65 | $0 | 7 | 2024-06-21 |
| EQRx, Inc. (EQRXW) Delisted | Director | 0 | $0.05 | $0 | $0 | 4 | 2023-11-09 |
| JAZZ | Director | 8,290 | $237.38 | $1.97M | -$3.76M | 23 | 2021-08-09 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Director | — | — | — | $0 | 2 | 2019-08-08 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | President and CEO | 0 | $10.19 | $0 | -$16.52M | 14 | 2016-06-24 |
| XENOPORT INC (XNPT) Delisted | Director | 15,000 | — | — | -$525.2K | 10 | 2016-05-19 |
| Cellectar Biosciences, Inc. (CLRB.Z) Delisted | Director | 117,371 | — | — | $248.8K | 1 | 2016-04-21 |
| Cellectar Biosciences, Inc. (CLRB.W) Delisted | Director | — | — | — | $0 | 2 | 2015-06-10 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Chief Executive Officer | 0 | — | — | -$4.14M | 22 | 2012-09-05 |
Recent Filings · Page 11 of 11
101 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-01-03 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Buy (P) | +2,500 | $7.6K | EDGAR |
Showing 101–101 of 101
Prev
Page 11 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.